Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan

• Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of global pharmaceutical companies

Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Dr. Makoto Sugita, M.D., Ph.D., MBA, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

Dr. Sugita is the former Vice President, and Head of R&D at Bristol Myers Squibb in Japan, a leading global biopharmaceutical company. He is a highly experienced medical professional having spent the past 20 years in R&D and commercial leadership positions within the Japanese businesses of global biopharmaceutical companies, including Johnson & Johnson/Janssen Pharmaceutical K.K. and AstraZeneca K.K., and Parexel, the global Contract Research Organization (CRO).

Dr. Sugita holds a Doctor of Medicine and Doctor of Philosophy (Ph.D.) from Tohoku University (Sendai, Japan) and an MBA from McGill University (Montreal, Canada).

Chris Cargill, President and CEO of Nxera, commented: “Dr. Sugita is an excellent addition to our team at Nxera. His exemplary credentials speak for themselves, and he is highly respected across the industry in Japan. His appointment, together with that of Toshihiro Maeda as Chief Operating Officer in January, highlights our ability to attract senior, highly talented and experienced pharma professionals who share our vision to become a leading biopharmaceutical company in Japan, and will be invaluable to helping us achieve this goal.”

Dr. Makoto Sugita added: “I am excited to join Nxera at a time when the company is making great progress building a competitive next-generation biopharma business in Japan. Nxera has developed a highly innovative pipeline across several important disease areas, and together with the opportunity to source external product development candidates I believe we can make a major difference to the lives of patients in Japan and globally.”